AstraZeneca Joins Hands with Roche, Qiagen for New blood-based drug to Benefit Lung Cancer Patients

AstraZeneca Joins Hands with Roche, Qiagen for New blood-based drug to Benefit L

AstraZeneca has signed up an agreement with Roche and Qiagen to develop liquid biopsy-based smart diagnostics for detection of cancer and the effectiveness of medicines among the patients. The companies will develop two separate diagnostic tests, both using simple blood samples to check the efficacy of cancer drugs from AstraZeneca.

Peer M. Schatz, Chief Executive Officer of QIAGEN, expressed that the collaboration with AstraZeneca will improve the treatment options for lung cancer patients.

The partnership will elaborate and speed up QIAGEN'S range of investments for liquid biopsy solutions for personalized healthcare. They are working to alter the aesthetics of treatments by introducing well grounded genomic tests based on blood samples or other body fluids. This will provide possibilities to physicians and the patients to deliver and track down the progress of treatments.

These tests will be developed, commercialized and accelerated via substantial network of laboratories. The diagnostics will be reliable enough to generate useful test content for QIA symphony family of automated instruments.

These tests depend on smart technology techniques, which will detect small fragments of circulating DNA in the plasma.

Mondher Mahjoubi, Senior Vice President, Global Product Strategy for Oncology at AstraZeneca, said: "By combining AstraZeneca's expertise in lung cancer with QIAGEN's diagnostic capabilities, we have the potential to transform the way specific tumor types are identified and treated". Patient's individualistic and accurate needs will be taken care of with the use of DNA testing.

The association with Qiagen demands to call upon a test that accompanies AstraZeneca's established lung cancer pill 'IRESSA', while with Roche will a companion to diagnose AstraZeneca's experimental successor to IRESSA called AZD9291.

IRESSA is an epidermal growth factor receptor-tyrosine kinase (EGFR-TK) inhibitor that acts to block signals for cancer cell growth and survival. This growth mutates in lung cancers, and these mutation-positive tumors are particularly sensitive to IRESSA. QIAGEN and AstraZeneca plan to benefit the identified patients with these mutations.

Share Share